Evolving Concern: Protection for Human Subjects
Просмотров: 62927 HRSAtube
https://www.ibiology.org/human-disease/hpv John Schiller provides an overview of HPV virus and infection, compares the three FDA approved vaccines against HPV, and explains the endpoints used in the clinical trials to prove vaccine efficacy. Talk Overview: Human Papillomavirus (HPV) causes 5% of all cancers worldwide, and the first vaccine against HPV was approved in 2006. In this seminar, Dr. John Schiller provides an overview of HPV virus and infection, compares the three FDA approved vaccines against HPV, and explains the endpoints used in the clinical trials to prove vaccine efficacy. After a decade of using the vaccine, retrospective studies now allow us to evaluate the possibility of using single-dose vaccination, which could lead to an increase in the general use of the vaccine (implementation), and improve HPV-related cancer prevention. In his second seminar, Schiller discusses the high efficacy of HPV vaccine, which is exceptionally good at producing neutralizing antibodies and also benefits from the low mutation rate of HPV. Coming to a better understanding of the efficacy of the HPV vaccine will provide evidence to support single-dose vaccination and aids in the development of new vaccines. Speaker Biography: Dr. John Schiller is a National Institute of Health (NIH) distinguished investigator and a professor at the National Cancer Institute at the NIH. Schiller completed his bachelor’s degree in molecular biology at the University of Wisconsin-Madison (1975), and received a doctorate degree in Microbiology at the University of Washington in Seattle (1982). Schiller continued his training at the Laboratory of Cellular Oncology as a National Research Service Award postdoctoral fellow. He became a senior investigator in 1986, and in 2016 he was designated as an NIH Distinguished Investigator. For his scientific contributions, Schiller received the National Medal of Technology and Innovation (2012), the American Society for Microbiology’s Joseph Public Health Award (2017), and the Lasker-DeBakey Clinical Medical Research Award (2017). Learn more about Schiller’s research at his lab website: https://ccr.cancer.gov/Laboratory-of-Cellular-Oncology/john-t-schiller
Просмотров: 2065 iBiology
Researchers in the NCI Division of Cancer Epidemiology and Genetics (DCEG) investigate the causes of cancer at the population level. Together with their trainees, our experts pair genetic and genomic studies of common and rare malignancies with classical epidemiological approaches. We utilize cutting-edge technology for large-scale processing of biological samples that yield data rich with clues to etiologic patterns. Families with rare inherited cancer syndromes, such as Li-Fraumeni syndrome, participate in DCEG clinical studies. Their contributions to research allow us to advance our understanding of genetic and modifiable factors in disease risk, and to generate cancer screening or prevention techniques for these unique populations. Watch our scientists discussing aspects of DCEG research in interviews done in conjunction with the American Society of Human Genetics (ASHG) https://dceg.cancer.gov/human-genetics Audio described version: https://youtu.be/NtgsodVLEX8
Просмотров: 456 National Cancer Institute
Inside NCI: A Conversation with Dr. Jonathan Wiest about Cancer Research Training The director of NCI's Center for Cancer Training discusses some of the challenges and opportunities of training the next generation of cancer researchers. http://www.cancer.gov/ncicancerbulletin/120109/page3?cid=YTncigov For Copyright Notice and Restrictions please visit our Web site at: http://www.cancer.gov/policies/page5?cid=YTncigov
Просмотров: 2961 National Cancer Institute
The National Cancer Institute offers postdoctoral training opportunities in cancer prevention and control. Application Period: May 1-August 25 Web: http://cpfp.nci.nih.gov Phone: 240-276-5626 Speakers: Ashley Felix, Ph.D., Cancer Prevention Fellow, 2011 Cohort. Maeve Mullooly, Ph.D., M.P.H., Cancer Prevention Fellow, 2013 Cohort. Krystle A. Lang Kuhs, Ph.D., M.P.H., Cancer Prevention Fellow, 2011 Cohort. Kristin Litzelman, Ph.D., Cancer Prevention Feloow, 2013 Cohort. Stephanie Fowler, Ph.D., M.P.H., Cancer Prevention Fellow, 2013 Cohort. Gary L. Ellison, Ph.D., M.P.H., Acting Branch Chief, Epidemiology and Genomics Research Program, NCI. Jocelyn A. Lee, Ph.D., M.P.H., Health Scientist Administrator, Office of Disease Prevention, NIH. Barnett S. Kramer, M.D., M.P.H., Director, Division of Cancer Prevention, NCI. David E. Nelson, M.D., M.P.H., Director, Cancer Prevention Fellowship Program, NCI. Application Period: May 1-August 25 Web: http://cpfp.nci.nih.gov Phone: 240-276-5626 U.S. Department of Health and Human Services National Institutes of Health | National Cancer Institute http://cpfp.nci.nih.gov 1-800-4-CANCER Produced June 2015
Просмотров: 2496 National Cancer Institute
Intel employee Bryce Olson was diagnosed with stage 4 prostate cancer. When the standard of care didn’t work, Bryce turned to genomic sequencing which allowed his doctors to identify specific genetic drivers of his disease and identify specific treatments and clinical trials that were a fit for his specific cancer. This precision medicine approach helped send his cancer into remission for several years. Now that his cancer has returned, Bryce is working with the Broad Institute and other leaders in the field of advanced cancer research to use artificial intelligence powered by Intel technology to discover new, innovative solutions that can help him and millions of others like him around the world. Learn more about the work Intel is doing to power the future of healthcare intelligence at intel.com/healthcare For more stories profiling pioneers of science and tech innovation, subscribe to Freethink at https://www.youtube.com/freethinkmedia And follow Freethink across other platforms here: Facebook: https://www.facebook.com/freethinkmedia Twitter: https://twitter.com/freethinkmedia Instagram: https://www.instagram.com/freethinkmedia Website: http://www.freethink.com
Просмотров: 2767800 Freethink
International Research Ethics: Experiences of researchers and participants in the field, and moving forward with ethics training Dr. Nancy Kass will outline the expectations and norms for research ethics generally and how they play out in some examples from low and middle income countries. Data will be presented from two studies: one with U.S. based researchers who conduct research in low and middle income countries about the ethics and IRB issues they have faced, and one with participants from clinical trials in LMIC settings. The presentation will then move to describing a large Fogarty-funded and Africa-based training program in research ethics, what it has tried to accomplish, what the successes and challenges have been, and strategies to evaluating such training programs. For an audio podcast preview, listen to The Rock's Podcasts. Nancy Kass Nancy Kass, ScD, is the Phoebe R. Berman Professor ofNancy Kass Bioethics and Public Health, in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health and Deputy Director for Public Health in the Berman Institute of Bioethics. In 2009-2010, Dr. Kass was based in Geneva, Switzerland, where she was working with the World Health Organization (WHO) Ethics Review Committee Secretariat. Dr. Kass received her BA from Stanford University, completed doctoral training in health policy from the Johns Hopkins School of Public Health, and was awarded a National Research Service Award to complete a postdoctoral fellowship in bioethics at the Kennedy Institute of Ethics, Georgetown University. Dr. Kass conducts empirical work in bioethics and health policy. Her publications are primarily in the field of U.S. and international research ethics, ethics and learning health care systems, HIV/AIDS ethics policy, public health ethics, and ethics of public health preparedness. She is co-editor of HIV, AIDS and Childbearing: Public Policy, Private Lives (Oxford University Press, 1996). Dr. Kass co-chaired the National Cancer Institute Committee to develop Recommendations for Informed Consent Documents for Cancer Clinical Trials, and served on the NCI's central IRB. She has served as consultant to the President's Advisory Committee on Human Radiation Experiments, to the National Bioethics Advisory Commission, and to the National Academy of Sciences. Current research projects examine ethics for a learning healthcare system including quality improvement and comparative effectiveness, informed consent in randomized trials, ethics issues that arise in international health research and ethics and public health preparedness. Dr. Kass teaches the Bloomberg School of Public Health's course on U.S. and International Research Ethics and Integrity, is the director of the School's PhD program in bioethics and health policy, and is the director of the Johns Hopkins Fogarty African Bioethics Training Program. Dr. Kass is an elected member of the Institute of Medicine and a Fellow of the Hastings Center.
Просмотров: 2023 Rock Ethics Institute
The National Institute of Nursing Research (NINR) Big Data in Symptoms Research Boot Camp, part of the NINR Symptom Research Methodologies Series, is a one-week intensive research training course at the National Institutes of Health (NIH) in Bethesda, Maryland. NINR's 2015 Boot Camp provided a foundation in data science focusing on methodologies and strategies for incorporating novel methods into research proposals. Since there was a high demand for the course, the first day of the Big Data Boot Camp was videocast live and is now available in segments on the NINR YouTube channel. To learn more visit www.ninr.nih.gov/bootcamp. Part 2 featured a keynote presentation by Dr. Eric Green, Director of the National Human Genome Research Institute (NHGRI).
Просмотров: 508 NINRnews
Learn about the different types of costs related to taking part in a clinical trial, and who is expected to pay for which costs. For more on clinical trials, visit https://www.cancer.gov/clinicaltrials To find NCI-supported clinical trials, go to https://trials.cancer.gov Need help finding a trial? Have a cancer-related question? Call, e-mail, or write the NCI Contact Center at https://www.cancer.gov/contact
Просмотров: 663 National Cancer Institute
A project created for my Advanced Writing class. If you liked this, go check out my main blog at http://ithinkincomics.wordpress.com/ ! The American Cancer Society is a nationwide, voluntary non-profit dedicated to eliminating cancer as a major health problem. They organize charity events such as Relay for Life and the Great American Smokeout. The website: http://www.cancer.org/index The many types of cancer: http://www.cancer.org/cancer/showallcancertypes/index The National Cancer Institute (NCI) is an agency of the US Department of Health and Human Services that runs the National Cancer program. The NCI both conducts its own and funds outside studies related to the prevention, diagnosis, and treatment of cancer. It also provides training programs for cancer research. The website: http://www.cancer.gov/ Definition of cancer: http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer Information on chemotherapy: http://www.cancer.gov/cancertopics/coping/chemotherapy-and-you/page2 The American Institute for Cancer Research (AICR) is a non-profit research organization supported by the World Cancer Research Fund. The AICR focuses on research of the prevention and treatment of cancer through everyday lifestyle changes, including weight control, diet, and exercise. The website: http://www.aicr.org/ Preventing cancer through everyday choices: http://www.aicr.org/reduce-your-cancer-risk/ Information on mitosis, cell senescence, contact inhibition, (when cells stop growing because it's too crowded) and basal cell carcinoma was taken from my genetics textbook. The book, Essential Genetics: A Genomics Perspective, Edition 5 by Daniel L. Hartl provides a solid foundation in gene mutation, expression, and heredity. For the truly curious, books can be purchased here: http://www.amazon.com/Essential-Genetics-Genomics-Perspective-Fifth/dp/0763773646/ref=sr_1_1?s=books&ie=UTF8&qid=1354381230&sr=1-1&keywords=Essential+Genetics%3A+A+Genomics+Perspective All sound effects were taken from freesound.org, a collaborative database with free-to-use, user-generated sound effects. The roaring cancer monster: http://www.freesound.org/people/Kodras/sounds/95827/ Dun-dun-dunnnn! http://www.freesound.org/people/copyc4t/sounds/146434/ The scientist thinking to himself: http://www.freesound.org/people/thecluegeek/sounds/140583/ The guy having an idea: http://www.freesound.org/people/ERH/sounds/32568/ A huge thanks to my writing teacher. Professor Musselman, and my peer reviewers Caleb and Michelle. Without them, this video would not have been possible!
Просмотров: 84159 artisticallycomical
Today, patients play important roles in cancer research at NCI. The history of patient advocacy has its roots in the social movements of the 1960s and 1970s. Watch this video to learn how patient advocates advanced the care and treatment of HIV/AIDS and how that helped shape cancer research advocacy at NCI. To learn how to get involved with research advocacy at NCI, visit http://advocacy.cancer.gov
Просмотров: 354 National Cancer Institute
My guest in this episode of The Doctor’s Farmacy is David Heber MD, PhD. Dr. Heber is the founding director of the UCLA Center for Human Nutrition, a professor of medicine and public health, and the founding chief of the division of clinical nutrition in the department of medicine. Dr. Heber also directs the National Cancer Institute-funded clinical nutrition research unit and the National Institute of Health’s nutrition and obesity training grants at UCLA. As if that wasn’t enough, Dr. Heber has published hundreds of articles and written 25 book chapters and two professional textbooks. Throughout his distinguished career, Dr. Heber has done primary research in the fields of obesity treatment and prevention, the role of nutrition, and phytochemicals. He’s an extraordinary physician and an inspiration to me. Tune into this brand new episode of The Doctor’s Farmacy for more! --- Dr. Hyman is a 10 time #1 New York Times bestselling author, family physician and international leader in the field of Functional Medicine. His podcast, The Doctor's Farmacy, is a place for deep conversations about the critical issues of our time in the space of health, wellness, food and politics. New episodes are released every Wednesday here on YouTube, and wherever you listen to podcasts. Find him and more of his content all over social media: Website http://www.drhyman.com/ Facebook https://www.facebook.com/drmarkhyman Instagram https://www.instagram.com/markhymanmd Twitter https://twitter.com/markhymanmd
Просмотров: 23784 Mark Hyman, MD
Dr. Jessica Winter is a nanotechnology cancer researcher who one day found herself to be a patient. Dr. Winter discusses her research in the Chemical and Biomedical Engineering departments at the Ohio State University, her initial diagnosis, what it's like to be on the other side of the treatment table, and her treatment at the Wexner Medical Center's James Comprehensive Cancer Center. Dr. Winter also discusses roadblocks in translating research from the bench to the bedside and how her illness has shaped her outlook on the future of cancer research. Professor Winter’s primary research interest is the exploration of the relationship between nanoparticles and biological elements. Her work is divided into three areas: Development of nanoscale neural prosthetic devices Patterned chemical and physical cues for improved neural adhesion and synapse formation Creation of oriented, nanopatterned surfaces using biological elements She is an established leader in nanobiotechnology through the development of magnetic quantum dots for cell and molecular separations. Winter is an Associate Professor of Biomedical Engineering and also Associate Professor, Chemical & Biomolecular Engineering at The Ohio State University. Her degrees include a B.S., Northwestern University, a M.S., University of Texas at Austin, 2001 and a Ph.D., University of Texas at Austin, 2004. In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)
Просмотров: 43083 TEDx Talks
https://www.ibiology.org/human-disease/hpv/#part-2 John Schiller provides an overview of HPV virus and infection, compares the three FDA approved vaccines against HPV, and explains the endpoints used in the clinical trials to prove vaccine efficacy. Talk Overview: Human Papillomavirus (HPV) causes 5% of all cancers worldwide, and the first vaccine against HPV was approved in 2006. In this seminar, Dr. John Schiller provides an overview of HPV virus and infection, compares the three FDA approved vaccines against HPV, and explains the endpoints used in the clinical trials to prove vaccine efficacy. After a decade of using the vaccine, retrospective studies now allow us to evaluate the possibility of using single-dose vaccination, which could lead to an increase in the general use of the vaccine (implementation), and improve HPV-related cancer prevention. In his second seminar, Schiller discusses the high efficacy of HPV vaccine, which is exceptionally good at producing neutralizing antibodies and also benefits from the low mutation rate of HPV. Coming to a better understanding of the efficacy of the HPV vaccine will provide evidence to support single-dose vaccination and aids in the development of new vaccines. Speaker Biography: Dr. John Schiller is a National Institute of Health (NIH) distinguished investigator and a professor at the National Cancer Institute at the NIH. Schiller completed his bachelor’s degree in molecular biology at the University of Wisconsin-Madison (1975), and received a doctorate degree in Microbiology at the University of Washington in Seattle (1982). Schiller continued his training at the Laboratory of Cellular Oncology as a National Research Service Award postdoctoral fellow. He became a senior investigator in 1986, and in 2016 he was designated as an NIH Distinguished Investigator. For his scientific contributions, Schiller received the National Medal of Technology and Innovation (2012), the American Society for Microbiology’s Joseph Public Health Award (2017), and the Lasker-DeBakey Clinical Medical Research Award (2017). Learn more about Schiller’s research at his lab website: https://ccr.cancer.gov/Laboratory-of-Cellular-Oncology/john-t-schiller
Просмотров: 752 iBiology
The National Cancer Institute’s Small Business Innovation Research (SBIR) Development Center provides special funding opportunities for small businesses through the Small Business Innovation Research/Small Business Technology Transfer program, one of the nation’s largest sources of financing for technology innovation. On June 14 at 1pm ET, join Michael Weingarten, Director of the NCI SBIR Development Center, and previous SBIR awardees Aruna Gambhir, CEO of CellSight Technologies and Guy Diperro, Founder of Chrono Therapeutics, as they discuss funding opportunities and entrepreneurial support provided by the NCI SBIR Development Center. http://www.cancer.gov/research
Просмотров: 845 National Cancer Institute
The chief of NCI's Pediatric Oncology Branch (http://pediatrics.cancer.gov/) talks about the research being done in her lab at NCI and areas of pediatric cancer research where researchers are poised to make major advances. The video was originally published in the NCI Cancer Bulletin http://www.cancer.gov/ncicancerbulletin/090710/page4?cid=YTncigov on September 7, 2010.
Просмотров: 2767 National Cancer Institute
For more information about this film, as well as links to other related content, please view our page on yourgenome: http://www.yourgenome.org/video/my-career-in-genomics-cancer-biology In this film Niki Patel talks about her research at the Wellcome Trust Sanger Institute looking at the genetics of cancer. This is one of a series of films providing a unique insight into different careers in the field of genomics.
Просмотров: 21081 yourgenome
National Cancer Institute The National Cancer Institute NCI is part of the National Institutes of Health NIH, which is one of eleven agencies that are part of the US Department of Health and Human Services The NCI coordinates the US National Cancer Program and conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship On April 1, 2015, Douglas Lowy, MD1 was named the Acting Director of NCI The National Cancer Institute mediates the majority of its mission via an extramural program that provides grants for cancer research Additionally, the National Cancer Institute has intramural research programs, which constitutes a small fraction of the overall National Cancer Institute budget, in Bethesda, Maryland and at the Frederick National Laboratory for Cancer Research2 at Fort Detrick, in Frederick, Maryland Contents 1 Legislative history 2 Anti-cancer drug investigations 3 Developmental Therapeutics Program 31 Method National Cancer Institute Click for more; https://www.turkaramamotoru.com/en/national-cancer-institute-33560.html There are excerpts from wikipedia on this article and video
Просмотров: 2 Search Engine
Dr. Eric Green, director of the National Human Genome Research Institute, gives an update on advances in human genome research. This interview originally aired Nov. 3, 2018.
Просмотров: 285 Mayo Clinic
On June 2, 2018, National Cancer Institute (NCI) Director Norman E. Sharpless, M.D. presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois regarding the power and promise of cancer research. He discussed his four key focus areas which are Basic Science, Workforce, Big Data and Clinical Trials. #ASCO18 https://www.cancer.gov/about-nci/leadership/director/presentations/sharpless-asco-2018
Просмотров: 1972 National Cancer Institute
Просмотров: 6179 U.S. Department of Health and Human Services
Dr. Majumder completed his predoctoral schooling at Saha Institute of Nuclear Physics in India and received his Ph.D. from New York University. He subsequently completed his postdoctoral training at Sloan Kettering Cancer Center and at Roche Institute of Molecular Biology. He joined The University of Texas M. D. Anderson Cancer Center in 1995 as an Assistant Professor and was promoted to his current position as Professor in 2006. His current research involves deciphering the mechanisms that control normal brain functions and how aberrations in these mechanisms causes diseased states such as cancer and neurodegenerative disorders. Dr. Majumder has a strong interest in teaching. In addition to leading a lab with undergraduate, graduate, postdoctoral and clinical fellows, he teaches at the Graduate School of Biomedical Sciences and organizes a biennial course at Cold Spring Harbor Laboratories on Brain Tumors. Dr. Majumder has received many awards including M. D. Anderson Fort Worth Living Legend Faculty Achievement Award, National Brain Tumor Society Chaiken Chair of Research Award, and B*CURED Research Award. Research Interests Mechanisms of normal development and diseased states in mammalian brain The research in my laboratory is focused on (1) deciphering the mechanisms that control normal development, (2) learning how aberrations in these mechanisms produces diseased states, and (3) investigating how such knowledge can be translated into improved patient care. In general, we begin by studying biological mechanisms and then build on the lessons learned from those studies using multiple methods including genomics, bioinformatics, biochemistry, cell biology, and mouse genetics. Our work involves close collaboration between basic scientists and clinicians. One of the first projects in my laboratory focused on advancing understanding of the childhood brain tumor medulloblastoma (MB) as a foundation for patient-specific therapeutic approaches. In the course of our early work, we discovered that the transcriptional repressor REST is aberrantly overexpressed in a subclass of MB tumors and that a unique role of REST in these MB tumors is to block differentiation of the cerebellar stem/progenitor cells. This work was exciting because we, using REST-VP16, and others, using HDAC- and DNMT1-inhibitors, could block REST function. Our work then evolved into an investigation of the mechanisms of stemness in neural stem cells, muscle progenitor cells, embryonic stem cells, and glioblastoma stem cells. Based on our understanding of these mechanisms, in one line of work, we converted muscle progenitor cells into functional neurons before the iPS system was published. Another line of work resolved some of the contradictions in the literature and showed that the REST-mediated regulation of ES cell pluripotency through a microRNA-mediated pathway depends on the cell type (not all ES lines are the same) as well as the culture conditions, indicating how various factors form part of an interconnected regulatory network. In a third line of work, we discovered that REST regulates glioblastoma (GBM) stem cell tumorigenicity by maintaining self-renewal and invasion. Importantly, high levels of REST characterize a class of human GBM patient tumors. Our recent genome-wide analysis followed by biochemical validation indicated that REST performs its functions in GSCs through a microRNA pathway (miR-124, a known REST target, and miR-203, a new target). In addition, using such genome-wide analyses, we discovered a new mechanism (miR-21-Sox2 regulatory axis)-based GBM patient classification with implications for precision medicine. We found that this classification identifies a distinct population of glioblastoma patients with distinguishable phenotypic characteristics and clinical outcomes. In yet another line of work, we generated conditional REST overexpression knockin mice to study REST function in the brain under physiological conditions. While studying the behavior of these mice, we found evidence suggesting that REST affects neurological and neuropsychiatric functions. We are currently using multiple methods to elucidate the role of REST in tumorigenesis and in neurological/neuropsychiatric conditions, and to examine implications for therapy.
Просмотров: 156 MD Anderson Cancer Center
September 28, 2011. Next-Gen 101: Video Tutorial on Conducting Whole-Exome Sequencing Research More: http://www.genome.gov/27545880
Просмотров: 6916 National Human Genome Research Institute
There is clear scientific evidence that supports the idea that lifestyle interventions like caloric restriction, fasting, and a ketogenic support the health of positive gene pathways, enhance the production of endogenous stem cells, power up the brain, increase the production of antioxidants, and even reduce inflammation. But there is no doubt that implementing these ideas, in terms of creating a workable diet, may well prove challenging. Our guest today on The Empowering Neurologist is Valter Longo, PhD. Dr. Longo has created a new dietary approach that in many ways mimics the effectiveness of the more difficult approaches described above, but at the same time is much easier to implement. He calls this diet the Fasting-Mimicking Diet, or FMD, and it is described in great detail in his new, best-selling book, The Longevity Diet. Let me tell you a little bit about Dr. Longo. He is the Edna M. Jones Professor of Gerontology and Biological Sciences, and Director of the Longevity Institute at the University of Southern California – Davis School of Gerontology, Los Angeles. He is also a Senior Group Leader at the IFOM, the FIRC Institute of Molecular Oncology Foundation and holds four professorships across top EU academic centers. Dr. Longo’s studies focus on the fundamental mechanisms of aging in simple organisms, mice and humans. The Longo laboratory has identified several genetic pathways that regulate aging in simple organisms and reduce the incidence of multiple diseases in mice and humans. His laboratory also described both dietary and genetic interventions that could reverse the course of Diabetes and Alzheimer’s and protect cells and improve the treatment of cancer and other diseases in mammals. Dr. Longo’s most recent studies are on dietary interventions that can affect stem cell-based regeneration to promote longevity in mice and humans. The Longevity Institute in Los Angeles, directed by Dr. Longo, includes over 40 faculty members focused on topics ranging from regeneration to dietary interventions aimed at improving health and lifespan in the near future. Among the accolades received by Dr. Longo are the 2010 Nathan Shock Lecture Award from the National Institute on Aging (NIA/NIH) and the 2013 Vincent Cristofalo “Rising Star” Award in Aging Research from the American Federation for Aging Research (AFAR). Dr. Longo is recognized as a global leader in aging and nutrition. With more than 106 peer reviewed publications in journals like Science, Nature, Cell, JAMA, Circulation, Cancer Cell, Journal of Translational Medicine, etc. He is recognized by Time Magazine, with three features in less than two years, as Longevity Guru. He is one of the most recently featured scientists by global media and news feeds. Dr. Longo was born and raised in Genoa, Italy and received his undergraduate degree from the University of North Texas, where he majored in biochemistry with a minor in jazz performance. He received his Ph.D. in Biochemistry from the University of California, Los Angeles (UCLA) in 1997 and his postdoctoral training in the Neurobiology of Aging and Alzheimer’s Diseases at USC. He started his independent career in 2000 at the University of Southern California, School of Gerontology, one of the first and leading programs for aging research and education. Today we will explore Dr. Longo’s research that went in to his creation of the fasting mimicking diet. I think you will find this to be a fascinating interview. I would also mention that all of the proceeds from his book, The Longevity Diet, are donated to charities as well as his ongoing research. You can find Dr. Longo, and follow his research, on Facebook.
Просмотров: 14261 DavidPerlmutterMD
Translational Research Training in Hematology (TRTH) provides junior researchers with a unique, year-long training and mentoring experience. The program is a joint effort of the European Hematology Association (EHA) and the American Society of Hematology (ASH) and is focused on helping early-career scientists build successful careers in hematologic translational research, including pathogenesis, diagnostics, and experimental treatment of hematological disorders.
Просмотров: 770 American Society of Hematology
September 13, 2010 - NHGRI Director Eric Green reports on institute progress — from its strategic planning process for the field of genomics to The Cancer Genome Atlas and the Human Microbiome Project — at the 60th meeting of the National Advisory Council for Human Genome Research (NACHGR). NACHGR advises the Department of Health and Human Services, the National Institutes of Health, and NHGRI on genetics, genomic research, training and programs related to the International Human Genome Project. More information on the meeting: http://www.genome.gov/27541171 NHGRI Director's Page: http://www.genome.gov/27527308
Просмотров: 852 National Human Genome Research Institute
https://www.ibiology.org/genetics-and-gene-regulation/canine-genetics/#part-2 Elaine Ostrander provides an overview of canine genetics, and explains how scientists are using genetics to decipher the molecular basis of different traits such as height and cancer risk. Talk Overview: Although all domestic dogs belong to the same species, different breeds display unique morphological traits and different disease susceptibility. Dr. Elaine Ostrander provides an overview of canine genetics, and explains how scientists are using genetics to decipher the molecular basis of different traits such as height and cancer risk. In her second lecture, Ostrander explains that canine genetics can be used to understand disease susceptibility and cancer risk. By analyzing the pedigree of dogs, her laboratory identified a series of genes involved in the elevated cancer risk of particular dog breeds. Specifically, her laboratory studied invasive transitional cell carcinoma of the bladder, a disease for which breeds like Scottish Terriers have a high susceptibility. In human cases of this disease, the cause is unknown in 50% of patients. Ostrander’s laboratory identified genetic mutations that explain the elevated cancer risk in these dogs. This information may improve diagnosis and targeted therapy in dogs and humans. Speaker Biography: Dr. Elaine Ostrander is the Chief and Distinguished Investigator at the National Human Genome Research Institute at the National Institutes of Health (NIH). She received her B.S. degree from the University of Washington (1981), and her Ph.D. from the Oregon Health & Science University (1987). Ostrander continued her postdoctoral training at Harvard University. A few years later, she joined the Lawrence Berkeley National Labs at University of California, Berkeley, where she began the canine genome project. In 2004, she joined the NIH and her laboratory studies the domestic dog as a model organism to understand the heritability of traits and disease susceptibility. For her scientific contributions, she was named NIH Distinguished Investigator (2011). Visit her lab website and learn more about Ostrander’s research: https://www.genome.gov/12513335
Просмотров: 777 iBiology
http://ncc.re.kr/english/index.jsp Today, one in four Koreans dies of cancer. Cancer is fast becoming one of the most serious diseases faced by not only Koreans, but for human kind, and this trend is forecasted to continue in the future. The battle to cure cancer through prevention, diagnosis, treatment, and research is being fought on both national and international levels. The World Health Organization (WHO) has said that one third of all cancers can be averted through preventive measures such as refraining from smoking and vaccination, another third can be completely cured by early detection, and the rest can be overcome through medical research. Ever since its inception in 2000, the National Cancer Center has persevered to lessen the burden of cancer for Koreans by conducting and offering assistance to cancer research, diagnosing and treating cancer patients, assisting in the National Cancer Control Initiatives, and finally, educating and training cancer specialists. Moreover, the NCC is aggressively backing the government's 2nd "10-year Cancer Control Plan (2006)" by devising cancer control policies, promoting cancer research in Korea, and by strengthening the cooperative network forged between Korean cancer-specialized medical institutions and international organizations. We hope the information carried by our website will help Koreans gain a deeper understanding of "cancer," and look forward to your continued support for our institution, as we strive on towards becoming Korea's suit of armor against this hazardous disease.
Просмотров: 108 김영희
Meet Jennie Leikin, a research scholar in the Laboratory for Human Carcinogenesis at the National Cancer Institute. Leikin's research involves looking at how cells communicate and contributes to trying to improve treatments for lung cancer. Leiken is participating in the Medical Research Scholars Program coordinated by the NIH Clinical Center's Office of Clinical Research Training and Medical Education. Video courtesy of LabTV https://www.labtv.com/Home#/ Interview conducted in 2014.
Просмотров: 24 NIH Clinical Center
Research advocates at NCI bring the patient experience and perspective to cancer research. This video describes the different ways patient advocates benefit research. Some patient advocates help with fundraising or shaping policy, while others support patients through education or outreach. Others help recruit for clinical trials. To learn how to get involved with research advocacy at NCI, visit http://advocacy.cancer.gov
Просмотров: 364 National Cancer Institute
Paul Sondel Reed and Carolee Walker Professor of Pediatrics, Human Oncology and Genetics Director of Research Division of Pediatric Hematology, Oncology and Bone Marrow Transplant University of Wisconsin - Madison Dr. Sondel’s career has focused on basic, translational and clinical cancer immunotherapy since beginning lab-studies in 1969. He completed both undergraduate (1971) and Ph.D. degrees in Genetics (1975) at UW, with guidance from Bone Marrow Transplant pioneer, Fritz Bach, M.D. With additional lab training in cancer immunology at the Dana Farber Center, he received his M.D. magna cum laude in 1977 from Harvard Medical School. Following residencies at the Universities of Minnesota and Wisconsin, he joined the UW faculty in 1980, and served as Head of Pediatric Hematology-Oncology and Bone Marrow Transplant from 1990 – 2016, and has helped lead the cancer immunology research effort at the UW Carbone Cancer Center since 1990. His laboratory has pursued several strategies for enabling immune responses to impact on cancer, and some have moved into clinical testing in children through the Children’s Oncology Group (COG), and some in adults at the UW Carbone Cancer Center, with some demonstrating clear clinical benefit. He has held multiple national committee and leadership roles, including at The National Institutes of Health, The American Cancer Society, The Children’s Oncology Group, The National Cancer Institute, and St. Jude’s Children’s Research Hospital. He has been a scholar of the Leukemia Society of America and recently received a 7-year Outstanding Investigator Award from the National Cancer Institute. He has published more than 370 scientific articles and chapters, and has trained more than 60 graduate students and post-doctoral fellows in his lab.
Просмотров: 41 Kevin Pomeroy
4th Annual NIH Conference on the Science of Dissemination and Implementation: Policy and Practice March 21-22, 2011 NIH Sponsored Training on Impact Evaluation Using Randomized Trials In Partnership with Abdul Latif Jameel Poverty Action Lab About the Workshop Rigorous impact evaluation is a critical ingredient in evidence-based policy. Within the health sector, randomized controlled trials (RCTs) are considered standard practice in clinical research. However, evaluation of programs and policies to implement large-scale health interventions tend to be far less rigorous. Much of this is due to the fact that researchers, health practitioners and policymakers are sometimes unsure of how to reconcile the rigor of clinical trials with the uncontrolled diversity of the field, particularly when operating in a developing country context. Political, logistical and ethical constraints can often make the ideal research design appear infeasible. The Abdul Latif Jameel Poverty Action Lab (J-PAL) is a network of empirical research economists who specialize in international development and have acquired substantial expertise running randomized evaluations in such settings. Researchers in the J-PAL network have adapted the driving characteristic of RCTs-- randomization of the treatment -- to test the effectiveness of health programs and policies in what are often difficult environments. J-PAL, in partnership with the NIH, is offering a workshop on how to incorporate rigorous impact evaluation methodologies into operations and implementation research (OR/IR). J-PAL researchers will share their experience evaluating programs on HIV/AIDS, immunization, maternal health, reproductive health, human resources for health and mobile health technologies. Using these case studies, they will cover the research design and implementation considerations necessary to conduct randomized evaluations. Through this workshop, participants will acquire many of the tools and lessons necessary to implement rigorous impact evaluations in a number of contexts and over a range of global health issues. Participants should be researchers, clinicians, or senior program managers with a Masters, PhD, or equivalent who are interested in implementation research. Some research background expected. Participants may come prepared with the details of a clinical or public health program/intervention that they are interested in studying, including the setting, context, and the size and characteristics of the target population. Sponsors U.S. Department of Health & Human Services (HHS) National Institutes of Health (NIH) John E. Fogarty International Center (FIC) National Cancer Institute (NCI) Office of Behavioral and Social Sciences Research (OBSSR)
Просмотров: 2563 NIHOD
There is considerable excitement about the use of stem cells for cardiovascular disease. Stem cells are unspecialized cells with the unique property to self-renew or make copies of themselves and to differentiate into specialized cells. The goal of stem cell therapy is to enhance the body's natural process of regeneration. There are a considerable number of stem cells currently under investigation for patients with heart attacks, angina, heart failure, and peripheral arterial disease. We have made considerable progress but have many questions left to answer. Timothy Henry, MD, FACC, is Chief of Cardiology at Cedars Sinai Heart Institute in Los Angeles, California. Dr. Henry earned his bachelor's degree at the University of North Dakota, graduated from medical school at University of California, San Francisco, in 1982, and was chief medicine resident from 1982--1986 at University of Colorado Health Sciences Center. He completed his training as a cardiology fellow, chief cardiology fellow, and interventional cardiology fellow at University of Minnesota in 1991. His research interests include interventional cardiology, acute myocardial infarction and novel therapies, including stem cell and gene therapy, for patients who are not candidates for standard revascularization techniques. Dr. Henry has published over 250 manuscripts and book chapters and has served on the Research Committee for the Minnesota Affiliate of the AHA and the Emergency Care Committee for the ACC; he currently serves on the Advisory Committee for the AHA Mission: Lifeline Program, the AHA Acute Cardiac Care Committee of the Council on Clinical Cardiology and on the ACC Interventional Subcommittee. He has served as national principal investigator of multiple large, multicenter trials in acute coronary syndromes, myocardial infarction and angiogenesis including several ongoing cardiovascular stem cell trials including RENEW, ALLSTAR and ATHENA. He is also principal investigator for 1 of 7 NIH Clinical Cardiovascular Stem Cell Centers. He is a fellow at ACC and SCAI and a member of Alpha Omega Alpha and the AHA Council on Clinical Cardiology. In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)
Просмотров: 156690 TEDx Talks
In this episode of the “Living outside the Matrix” Podcast, Nigel Howitt hears about the root causes of the paradigm shift occurring in health care from Dr Zach Bush MD. Dr Zach Bush is a triple board-certified Medical Doctor in the USA. He has expertise in Internal Medicine, Endocrinology and Metabolism, as well as Palliative care. He is an internationally recognized educator on the microbiome and nutrition. He and his team have discovered some profound new insights into human health and longevity that have a huge bearing on what we know about the foundations of human health. Modern 'health care' is actually no such thing, it has become disease management. Step outside the Matrix and learn the basic requirements of how to ensure your own optimal health and longevity. Dr Bush is at the cutting edge of new scientific discoveries impacting our whole understanding of the concept of health and wellbeing. Timings are approximate: 05:20 – Variations in the microbiome profile associated with specific diseases and cancers. 05:45 – Cancer is not a genetic disease, medicine is equipped to manage disease not help achieve health. 07:13 – Epigenetics and the human genome. 09:23 – The environment can methylate genes, turn them on or off. It’s the non-coding sequences of the genome that do the switching through micro RNA. 11:00 – junk DNA. Really? 13:30 – 35-40% of micro RNA is NOT human. It comes from bacteria, fungi and other microbes as well as our food; food is a genomic download. 15:00 – The problems of factory farming. 18:00 – Growing our own food is currently part of the solution. 19:30 – Glyphosate: Kills single-celled organisms, blocks the Shikimate pathway preventing the production of 3 essential amino acids Phenylalanine, Tyrosine and Tryptophan. 23:00 – Rather than biting the hand that feeds, this is killing the hand that feeds! 24:00 – Blocking the production of the Alkaloids that ensure the medicinal qualities of food. 29:30 – Dr Bush starts his nutrition clinic in 2008 after a funding collapse for his research in academia. 33:30 – Redox molecules made by bacteria found in the soil. 34:00 – Cell to cell communication. 36:00 – Gut health is diversity. 37:00 – up to 90& loss of diversity after a course of antibiotics. 37:30 – Probiotics not a complete solution. 39:25 – Gut health is the integrity of the gut lining. 40:30 – A description of the gut lining. 41:30 – tight junctions. 42:00 – Gut health is a strong immune system. 42:30 - Glyphosate destroys gut health. 44:30 – Detailed of the break up of the gut lining. Check out https://shop.restore4life.com for more information and to see real-time video footage. 45:30 – Gluten sensitivity. 46:24 – Glyphosate effectively inhibits production of glutathione, the main antioxidant that supports acute inflammation. 46:30 – acute versus chronic inflammation. 47:45 – Good news! Redox molecules found in ancient soil. 49:00 – massive ecosystem and diversity feeding the dinosaurs. 50:00 – extracting Redox molecules from ancient soils. 50:50 – Restore added to human biology changes everything. 51:15 – Mainstream medicine has been studying human physiology in a petri dish, in sterility – out of context. 52:40 – Cell to cell communication, the opposite of cancer. 53:00 – it is isolated cells that continuously replicate as cancer. 54:00 - Chronic inflammation is the root of all disease and how redox molecules deal with it. 57:20 – After 3 months on Restore patients exhibit all the signs of a healthy gut. 58:20 – The liquid circuit board that is RESTORE triggers a huge cooperative operation between the microbiome and human protein production. 59:00 – 800-fold increase in glutathione production. 1:00:00 – Get out of the Matrix mindset that sees germs (microbes) as the problem. 1:03:00 – How does a buildup of Chronic inflammation prevent us from being healthy? 1:04:30 – the 3 levels of cell to cell communication. 1:09:00 – How all 3 of these affect the mitochondria. Plus background on Mitochondria. 1:11:50 – The story of cellular repair is redox signalling by mitochondria governed by the redox signalling of the microbiome. 1:12:30 – Longevity, cellular repair and the positive impact of redox molecules/RESTORE. 1:16:00 – no need to (and no point in trying to) micro-manage the immune system. 1:19:00 – The need for supplements? 1:21:45 – The secret to health is to connect with the environment. Grounding and breathing in the microbes to populate the gut. For more information about Dr Zach Bush visit http://zachbushmd.com For more information about Dr Bush’s product RESTORE visit: https://shop.restore4life.com To buy RESTORE in the UK visit https://www.good4thegut.com/ and they can ship to anywhere in the world. For a free gut health checklist visit https://www.good4thegut.com/blog/free-gut-health-check-list/ Music: "Awaken", https://soundcloud.com/user-391111134/awaken/ Video release & publication Mark Mage, https://amzn.to/2D1EWVL
Просмотров: 21146 Lawful Rebel
October 16, 2007 Lecture Title: Genomic Information The 2007 Jeffrey M. Trent Lectureship in Cancer Research presented by Eric S. Lander, Ph.D., founding director of the Broad Institute of M.I.T. and Harvard. More: http://www.genome.gov/26023567
Просмотров: 10118 National Human Genome Research Institute
The Johns Hopkins Institute for Clinical and Translational Research worked with the Whiting School of Engineering to establish an Engineering Collaborative for Patient Safety, with the purpose of bringing engineering talent together with to clinicians, to analyze priority patient safety issues. Learn more at: http://ictr.johnshopkins.edu/collaboration/collaboration-mentoring-training/training-education/patient-safety-collaborative/
Просмотров: 1404 Johns Hopkins Medicine
Hear what important cancer community stakeholders from the patient, oncology, research and drug development communities have to say about the critical importance of high-quality biospecimens and biorepositories for cancer research and patient care. Learn more about the National Cancer Institute's efforts in the critical area of biospecimens and biorepositories at http://biospecimens.cancer.gov/ . For Copyright Notice and Restrictions please visit our Web site at: http://www.cancer.gov/policies/page5?cid=YTncigov
Просмотров: 1762 National Cancer Institute
Moderator: Ellen Wright Clayton, MD, JD, Craig-Weaver Professor of Pediatrics; Professor of Law; Professor of Health Policy, Co-Founder, Center for Biomedical Ethics and Society, Vanderbilt University • Wylie Burke, MD, PhD, Professor, Department of Bioethics and Humanities; Member, Fred Hutchinson Cancer Research Center, University of Washington This conference was part of a two-day event, Frontiers in Research Ethics, which consisted of three components: • An all-day conference on March 8, 2017, The Future of Informed Consent in Research and Translational Medicine • A half-day conference the morning of March 9, 2017, The Challenges of Informed Consent in Research with Children, Adolescents & Adults • Trainings and workshops held the afternoon of March 9, 2017. These were not recorded. It’s been more than 100 years since the landmark Schloendorff v. Society of New York Hospital decision, in which the court articulated a foundational concept of bioethics: “Every human being of adult years and sound mind has a right to determine what shall be done with his own body.” This national conference brought together renowned speakers from a variety of disciplines who addressed how informed consent ethics and policy have developed over the past century, and what tools are needed to improve patient and research participant protections going forward. Discussion included recent changes to the Common Rule governing research, including changes on informed consent and broad consent. Sponsored by the Consortium on Law and Values in Health, Environment & the Life Sciences and Masonic Cancer Center, University of Minnesota. Also supported in part by the National Human Genome Research Institute (NHGRI) & National Cancer Institute (NCI), National Institutes of Health grant #1-R01-HG008605.
Просмотров: 10 University of Minnesota Consortium on Law & Values
Recorded: February 5, 1996 Director of the National Institutes of Health Harold Varmus, M.D., co-recipient of a Nobel Prize for studies of the genetic basis of cancer, was nominated by President Obama as Director of the National Cancer Institute on May 17, 2010. He began his tenure as NCI Director on July 12, 2010. He previously served as President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center (MSKCC) and as Director of the National Institutes of Health (NIH). Much of Varmus' scientific work was conducted during 23 years as a faculty member at the University of California, San Francisco, Medical School, where he and Dr. J. Michael Bishop and their co-workers demonstrated the cellular origins of the oncogene of a chicken retrovirus. This discovery led to the isolation of many cellular genes that normally control growth and development and are frequently mutated in human cancer. For this work, Bishop and Varmus received many awards, including the 1989 Nobel Prize for Physiology or Medicine. Varmus is also widely recognized for his studies of the replication cycles of retroviruses and hepatitis B viruses, the functions of genes implicated in cancer, and the development of mouse models of human cancer (the focus of much of the work in his laboratory at MSKCC). In 1993, Varmus was named by President Clinton to serve as the Director of NIH, a position he held until the end of 1999. During his tenure at NIH, he initiated many changes in the conduct of intramural and extramural research programs; recruited new leaders for most of the important positions at NIH; planned three major buildings on the NIH campus, including the Mark O. Hatfield Clinical Research Center ; and helped to initiate the five-year doubling of the NIH budget. At MSKCC, Varmus emphasized opportunities to harness advances in the biological sciences to improve the care of patients with cancer. Under his leadership, the scientific programs were reorganized and enlarged; a new research building, the Mortimer B. Zuckerman Research Center, was constructed; and new graduate training programs were established in chemical biology and computational biology (as part of a new Tri-Institutional Research Program with Rockefeller University and Weill-Cornell Medical College) and in cancer biology (through MSKCC's first degree-awarding program in the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences). In addition, he oversaw the construction of new clinical facilities (for pediatrics, pathology, urology, and surgery) and new centers for breast cancer treatment and imaging (the Evelyn H. Lauder Breast Center and the MSKCC Imaging Center); the founding of a hospital-based program in translational research (the Human Oncology and Pathogenesis Program ); and the development of the Tri-Institutional Stem Cell Initiative and the Starr Cancer Consortium, involving five research institutions. To ensure that MSKCC was promoting high-quality cancer care for all citizens of New York and equal opportunities for its employees, he helped to found and oversee a new cancer clinic in central Harlem (the Ralph Lauren Center for Cancer Care and Prevention) and new programs for diversity and gender equity (the Office of Diversity Programs in Clinical Care, Research, and Training and the Women Faculty Affairs Program). Varmus has authored over 300 scientific papers and five books, including an introduction to the genetic basis of cancer for a general audience and a memoir, The Art and Politics of Science, published in 2009. He has been an advisor to the Federal government, pharmaceutical and biotechnology firms, and many academic institutions, and was appointed by President Barack Obama as co-chair of the President's Council of Advisors on Science and Technology (PCAST). He served on the World Health Organization's Commission on Macroeconomics and Health from 2000 to 2002; is a co-founder and Chairman of the Board of Directors of the Public Library of Science, a publisher of open-access journals in the biomedical sciences; chaired the Scientific Board of the Grand Challenges in Global Health at the Bill and Melinda Gates Foundation from 2003 to 2008 and now chairs the Foundation's Global Health Advisory Committee; and is involved in several initiatives to promote science in developing countries, including the Global Science Corps, through the Science Initiatives Group. He was also a member of the Funding Committee of the Empire State Stem Cell Board and serves as co-chair of the Institute of Medicine's committee on "The U.S. Commitment to Global Health." He has been a member of the U.S. National Academy of Sciences since 1984 and of the Institute of Medicine since 1991, and has received the National Medal of Science, the Vannevar Bush Award, and several honorary degrees and other prizes, in addition to the Nobel Prize.
Просмотров: 76 Landon Lecture Series
ClinicalTrials.gov website - https://clinicaltrials.gov/ NIH Requirements for Registering & Reporting NIH-funded Clinical Trials - https://grants.nih.gov/policy/clinical-trials/reporting/index.htm NIH Policy on the Dissemination of NIH-funded Clinical Trial Information - https://grants.nih.gov/policy/clinical-trials/reporting/understanding/nih-policy.htm Guidelines for Registering with ClinicalTrials.gov - https://www.research.uci.edu/compliance/human-research-protections/researchers/guidelines-for-registering-in-a-clinicaltrialsgov-registry.html
Просмотров: 75 UCI Office of Research
Dr. Jake Kushner is a McNair Medical Institute Scholar and an Associate Professor at the Baylor College of Medicine. For 6 years he served as Chief of Pediatric Diabetes and Endocrinology at the Baylor College of Medicine and Texas Children’s Hospital. His overarching career goal is to help children, adolescents, and young adults with type 1 diabetes and other endocrine disorders to live long, healthy lives. A graduate of the University of California at Berkeley, Dr. Kushner earned his medical doctorate from Albany Medical College followed by pediatrics residency at Brown, pediatric endocrinology fellowship at Children’s Hospital Boston, and a 5-year research fellowship at the Joslin Diabetes Center (both of Harvard Medical School). Prior to arriving at the Baylor College of Medicine Dr. Kushner was at the University of Pennsylvania School of Medicine and the Children’s Hospital of Philadelphia. The overall goal of his basic science research program is to enable regeneration of the insulin-secreting pancreatic beta cells as novel therapies for diabetes patients. Dr. Kushner has received numerous national honors, including a Basil O’Connor award from the March of Dimes and elected membership to the American Society of Clinical Investigation. He has also served as president of the Society for Pediatric Research. His research has been supported by the National Institutes of Health, the Juvenile Diabetes Research Foundation, and other sources. Dr. Kushner serves as an advisor to Lexicon Pharmaceuticals, Virta Health Inc., and the T1D Exchange. He is the current chair of DDK-B, an NIH study section that reviews training applications in diabetes research. Dr. Kushner’s clinical interests center around the care of children, adolescents, and young adults with type 1 diabetes.
Просмотров: 8903 Low Carb Down Under
This video was produced by the research center entitled Weaving an Islander Network for Cancer Awareness Research and Training in an effort to raise awareness about health issues that affect Pacific Islander communities. This video was made possible by Grant Number U54CA153458 from the National Cancer Institute to Reduce Cancer Disparities. Its contents are solely the responsibility of WINCART and do not necessarily represent the official views of the National Cancer Institute. Media production services provided by Royce Entertainment Group and Cut & Spliced Productions. Find out more at http://wincart.fullerton.edu/ or http://www.cutandspliced.com.
Просмотров: 178 cutandspliced
In partnership with the Centre for Global Studies and the POLIS Project on Ecological Governance, UVic Law presents this two-hour panel discussion and Continuing Legal Education (CLE) course on this case of national significance. Panelists include: Jay Nelson (General Counsel to the Tsilhqot'in Nation, Associate Counsel at Woodward & Company), Krista Robertson (Lawyer at JFK Law Corporation with expertise in Aboriginal Rights Law) and Dr. John Borrows (Canada Research Chair in Indigenous Law at the University of Victoria).
Просмотров: 6562 UVic Law
We live in the age of the great discovery, scientists armed with the new sequencing technology explore and map DNA in the genomes of all the living species. Although this is an expensive task, a group of underfunded scientists turns to the local community and raises enough money to publish a genome of an endangered species of parrots. Is this an example of how science is going to develop in the future? Vivimos en la edad del gran descubrimiento; científicos equipados con nuevas tecnologías de secuenciación exploran y mapean DNA en los genomas de todos los organismos vivientes. Un grupo de científicos con fondos cortos. Dr. Taras Oleskyk is a native of Ukraine who came to Puerto Rico from the US to study genome biology of the island. He holds a MS from BGSU (Bowling Green,OH), PhD from the University of Georgia (Athens, GA) and have postdoctoral training at the National Cancer Institute (Frederick, MD). His research efforts today are directed towards sequencing and assembling genomes of endemic and endangered Caribbean vertebrates, specifically the critically threatened Puerto Rican parrot (Amazona vittata). Genomes of other two vertebrate species are under way, and in the future genomes of all Amazon parrots will be sequenced to provide an genome-wide model to study evolution of vertebrate species on islands. He has been speaking internationally on how to involve the local community into supporting genome science and how to excite undergraduate students about scientific careers, genomics and conservation of the endangered species from their native island. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Просмотров: 1472 TEDx Talks
Josep graduated in Medicine and Surgery at the University of Barcelona, Catalonia. Soon after graduating, he moved to Stoke-on-Trent where he carried out his training in Oncology at the North Staffordshire Royal Infirmary. Josep has had always an interest in cancer research and following 4 years training in Stoke-on-Trent, he moved to the National Cancer Institute in Milan, Italy. He spent 2 and a half years in Milan developing his research career on cancer immunotherapy and gene therapy. Following this time, he moved back to Stoke-on-Trent in 1995 where he has been working ever since, combining his clinical work in Oncology at UHNM with basic and translational research at the Institute for Science and Technology in Medicine at Keele University. He got his PhD degree at Keele University. His research spans from enhancing oncological patients’ satisfaction with their management (he won the UHNM Staff award for patient experience in 2012) to improving the early diagnosis of cancer using spectrometry and spectroscopy techniques. He was involved in the development of one of the beamlines at Diamond Light Source, Oxfordshire (one of the major research facilities in the UK) and is a founding member of the International Society for Clinical Spectroscopy. He has been a member of different International Committees, an invited speaker at several international meetings, has supervised to success several PhD students, and his work has been publicised not only in the written press nationally but also in the BBC 10 o’clock news (national news). He has also recently been involved in the creation of a Master Medical Science Course in Oncology where its novelty sits on students combining clinical activities with basic research in oncology. The application of breath analysis in the management of disease goes back to ancient Greece when Hippocrates described fetor oris (halitosis) and fetor hepaticus (a sign of liver failure). Since then, people have been aware through observation that some breath smells were related to certain diseases. A major breakthrough was achieved when Linus Pauling described in 1971 over 200 different Volatile Organic Compounds (VOCs) in human exhaled air and in urine headspace. The use of breath analysis as a non-invasive tool to manage diseases has clear examples in the [13/14C] urea breath test used in the diagnosis of Helicobacter pylori infection and the nitric oxide (NO) breath test in the diagnosis of airway inflammation. Present techniques can now measure VOCs in the range of parts per million (ppm) to parts per trillion (ppt) by volume. The identification of VOCs in the breath of patients with cancer, specially lung cancer, has attracted a lot of interest in the last few years. While several studies including ours have been able to differentiate between cancer cells and non-malignant cells grown in vitro based on their VOCs’ profile in the headspace cultures, the in vivo studies have provided conflicting results. Several factors such as the origin of the VOCs (from tumour cells and/or tumour microenvironment), sample collection and VOCs detection need still to be tackled before breath analysis can make it into clinical practice. This Inaugural Lecture will discuss some of these issues and the work carried out using the Selected Ion Flow Tube Mass Spectrometry (SIFT-MS) for VOCs analysis specially in lung cancer.
Просмотров: 189 Keele University
The NIH Office of Research on Women’s Health, along with the FDA’s Office of Women’s Health, invites you to watch this interactive and engaging panel discussion held during National Women’s Health Week (May 2015). This panel event celebrates and recognizes the importance of women and diversity in clinical research. You’ll hear from volunteers who have participated in clinical research at NIH and the professionals that support them and our health advances. Find out what it's like to be involved in a study; learn about the ethical issues and protections surrounding participation; and discover the support, triumphs, and challenges that surround this critical enterprise. Participants include: Janine Clayton, M.D., NIH Associate Director for Research on Women’s Health and Director, Office of Research on Women’s Health Lauren V. Wood, M.D., Senior Clinical Investigator, Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH Laura M. Lee, M.Sc., RN, Special Assistant to the Deputy Director for Clinical Care and Patient Safety and Clinical Quality Officer, NIH Clinical Center Jamie Gentille, clinical trial volunteer Juliana Ejedoghaobi, clinical trial volunteer Amina White, M.D., M.A., Department of Bioethics, NIH Clinical Center Adrienne Farrar, Ph.D., LCSW-C, LICSW, Chief, Social Work Department, NIH Clinical Center Lori Wiener, Ph.D., Co-Director, Behavioral Science Core; and Director, Psychosocial Support and Research Program, Pediatric Oncology Branch, Center for Cancer Research, NIH National Cancer Institute Marsha Henderson, M.C.R.P., Assistant Commissioner for Women’s Health, FDA
Просмотров: 493 NIHOD
Tyrone B. Hayes, PhD - Friday Luncheon Class of 43 Chair and Professor of Integrative Biology University of California, Berkeley Dr. Tyrone B. Hayes was born and raised in Columbia, South Carolina, where he developed his love for biology. He received his bachelor’s degree from Harvard University in 1989 and his PhD from the Department of Integrative Biology at the University of California, Berkeley, in 1993. After completing his PhD, he began post-doctoral training at the National Institute of Child Health and Human Development, National Institutes of Health, and the Cancer Research Laboratories at UC Berkeley (funded by the National Science Foundation), but this training was truncated when he was hired as an assistant professor at UC Berkeley in 1994. He was promoted to associate professor with tenure in 2000 and to full professor in 2003. Hayes’ research focuses on developmental endocrinology with an emphasis on evolution and environmental regulation of growth and development. For the last 15 years, the role of endocrine disrupting contaminants, particularly pesticides, has been a major focus. Hayes is interested in the impact of chemical contaminants on environmental health and public health with specific interests in the role of pesticides in global amphibian declines and environmental justice concerns associated with targeted exposure of racial and ethnic minorities to endocrine disruptors and the role that exposure plays in health care disparities.
Просмотров: 1928 SACNAS
Rejuvenation Biotechnology 2014 Cancer Session (August 22, 2014, 1:00pm) "Cancer and Aging: Rival Demons?" Presenter: Judith Campisi, Professor, Buck Institute for Research on Aging. Judith Campisi received a PhD in Biochemistry from the State University of New York at Stony Brook, and postdoctoral training in cell cycle regulation and cancer at the Dana-Farber Cancer Institute and Harvard Medical School. As an Assistant Professor at the Boston University Medical School, she began to focus her laboratory on role of cellular senescence in suppressing the development cancer, but soon became convinced that senescent cells also contributed to aging. She left Boston University as an Associate Professor to accept a Senior Scientist position at the Lawrence Berkeley National Laboratory in 1991. In 2002, she established a laboratory at the Buck Institute for Age Research, where she is a Professor. At both institutions, Campisi established a broad program to understand various aspects of aging, with an emphasis on the interface between cancer and aging. Her laboratory made several pioneering discoveries in these areas. In recognition of the quality of her research and leadership, Campisi received numerous awards, including two MERIT awards from the US National Institute on Aging, awards from the AlliedSignal Corporation, Gerontological Society of America and American Federation for Aging Research, and the Longevity prize from the IPSEN Foundation. She serves on numerous national and international editorial and advisory boards. Visit http://www.sens.org/videos/rejuvenation-biotechnology-2014 to view the rest of our RB2014 videos.
Просмотров: 3002 SENS Foundation